AstraZeneca's Covid-19 vaccine performed better than expected in final trials, which will most likely be allowed back in the United States and boost the confidence of many after much criticism in Europe.
The vaccine manufacturer reported on Monday that trials conducted in Chile, Peru and the United States found that the vaccine, developed in conjunction with Oxford University, had an efficacy level of up to 79% in preventing Covid-19 and most importantly did not pose a risk of blood clots. AstraZeneca plans to apply for authority from the U.S. back next week.
Previously several countries mostly from Europe, including Germany and France had stopped the use of the AstraZeneca vaccine after several reports stated that the vaccine had side effects of blood clots. Following that, the WHO has stated that the vaccine is safe. But people are still skeptical of the matter.
With the latest efficacy level reports, it is expected that the public will begin to regain confidence in the AstraZeneca vaccine. The vaccine has also been the center of conflict between the UK and the European Union over the issue of ‘vaccine nationalism’.
Recent data shows more than 32,000 people have been vaccinated in the latest trial with elderly volunteers more predominant. The results found that this trial showed an effectiveness level of 79% compared to the previous only 60%.
AstraZeneca shares rose more than 1% in early London trading.
Last Friday, British Prime Minister Boris Johnson received his first injection. He stated that, he did not feel any side effects.
